Xi Venture Capital leads investment in hundreds of millions of yuan in a new round of financing for Jianshe Medical

　　Recently, Jianshi Medical Technology Group announced a new round of financing worth hundreds of millions of yuan, led by Xichuang Capital and Binhu State Investment, with well-known American medical device industry partners following suit. This round of financing will be used for product research and development, expansion of production, and subsequent domestic and international commercial expansion at the Healthy Wuxi base.

　　Jianshi Medical is an emerging medical technology enterprise in China, focusing on the three major disease areas of minimally invasive surgery, vascular intervention, and structural heart disease, and has become a local leading brand in related fields. Jianshi Medical has multiple leading products and is the first local enterprise in China to be approved for high-tech equipment products such as electric endoscopic staplers, antibacterial sutures, intracranial thrombectomy stents, and interventional aortic valves. Jianshi already has multiple high-end R&D and production bases in China. In November 2022, the R&D and production base of Jianshi located in Binhu, Wuxi was officially put into operation. The base benchmarks the world's advanced medical technology enterprises in manufacturing processes and large-scale production, and is equipped with high-level production capabilities. As of now, Jianshi's products have entered more than 2000 large and medium-sized hospitals in China, and are exported to international markets such as Europe, America, and South Korea.

　　Fu Haiying, Managing Director of the Biomedical Team in the Investment Business Department of Xicheng Venture Capital, stated that Jianshi Medical has achieved full chain integration of medical device production, research and development, clinical trials, registration, and sales. After several years of development, it has grown into a domestic device leader with fully verified comprehensive competitiveness. At the same time, we believe that in the current context of industrial upgrading and going global, industry integrators like Jianshi and medical device companies with international capabilities have outstanding advantages in independent innovation and research and development, centralized procurement and volume, and international cooperation, and have strong risk resistance. The dual support of Chinese investors and American industrial investors this time will further strengthen the business expansion of Health Care in key areas, provide more innovative therapies, and save patients' lives.